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Abstract: This article reviews and updates published data on cefditoren. The in vitro activity 
of cefditoren and its potential pharmacokinetic/pharmacodynamic adequacy to cover emerging 
resistance phenotypes in the present decade is reviewed. Cefditoren’s in vitro activity against 
most prevalent bacterial respiratory pathogens in the community and its pharmacokinetic/
pharmacodynamic profile suggests a significant role for cefditoren in the treatment of respira-
tory tract infections. Clinical trials (in acute exacerbations of chronic bronchitis, community-
acquired pneumonia, pharyngotonsillitis, and sinusitis) performed during clinical development 
outside Japan, mainly in adults, are reviewed, together with new clinical studies in the treatment 
of pharyngotonsillitis, sinusitis, and otitis media in children, mainly in Japan, for efficacy and 
safety assessment. The results of these studies support the adequacy of cefditoren for the treat-
ment of community-acquired respiratory tract infections with a safety profile similar to previous 
oral antibiotics. From the data reviewed, it is concluded that cefditoren is an adequate option 
for the treatment of mild-to-moderate community-acquired respiratory infections, especially 
in geographical areas with a reported prevalence of phenotypes exhibiting nonsusceptibility to 
common oral antibiotics.
Keywords: acute exacerbations of chronic bronchitis, community-acquired pneumonia, 
pharyngotonsillitis, sinusitis, otitis media
Introduction: resistance issues and the development 
of new antibiotics
Appropriate use of antimicrobials is defined by the World Health Organization as “the 
cost-effective use of antimicrobials which maximizes clinical and therapeutic effect 
while minimizing both drug-related toxicity and the development of antimicrobial 
resistance.”1 Antimicrobial resistance is one of the most urgent health threats people 
face all around the world2 and is emerging to every class of existing antibiotics, affect-
ing environments, hospitals, and the community.3
Increasing awareness of optimizing therapy not only involves maximizing thera-
peutic outcome but also minimizing the risk of resistance emerging during therapy, 
both in the infecting pathogen and in the normal flora.4 While optimizing outcome 
is directed at the individual patient level, emergence of resistance is an ecological 
issue and a trade-off between these two objectives is not easy to achieve.4 There is 
a dynamic situation in which the introduction of new antimicrobials necessitated by 
the emergence of resistance to existing compounds produces new selective pressure 
that selects new resistances, thus closing the circle. Therefore, resistance selection 
and diffusion in the community derived from antibiotic consumption requires, in turn, 
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new antibiotics. However, a new antibiotic is only needed if 
it can counter existing resistances and if it possesses limited 
capability of resistance selection in human microbiota 
(“ecological effect”).
Around 85%–90% of antibiotic consumption occurs 
in the community, with 80% of this consumption for the 
treatment of respiratory tract infections.5 The most preva-
lent bacterial isolates causing respiratory infections in the 
community (Streptococcus pneumoniae, Streptococcus 
pyogenes and Haemophilus influenzae) are part of normal 
flora in humans, with the nasopharynx as the exclusive host. 
Antibiotic consumption can select resistant populations or 
subpopulations present in the nasopharynx that can be further 
transmitted to other individuals.
S. pneumoniae is a natural transformable bacterial 
pathogen showing rapid evolution in response to clinical 
interventions. Following the introduction of the 7-valent 
pneumococcal conjugate vaccine (PCV7) for immunization 
in children, the incidence of invasive pneumococcal disease 
has declined both in children and adults (reflecting “herd 
immunity”).6 The decrease in the incidence of invasive dis-
ease caused by serotypes included in PCV7 runs in parallel 
with decreases in nonsusceptibility to penicillin (oral) and 
erythromycin among invasive isolates, from both adults and 
children,7,8 but not among noninvasive isolates such as those 
from middle-ear fluid.9 However, emergence of serotypes not 
encompassed by the vaccine is worrisome and may be associ-
ated with heightened antimicrobial resistance and virulence.6 
In Spain, recent published data show that nonsusceptibility 
rates to penicillin/erythromycin are around 20% among 
invasive isolates8 but around 45%–50% among middle-ear 
isolates.9 Worldwide, approximately 30% of isolates are resis-
tant to macrolides10 and a similar percentage of S. pneumoniae 
are now considered multidrug resistant.11 In contrast, rates of 
resistance to fluoroquinolones are still low.12
However, antibiotic pressure does not always result in 
the emergence of resistance. In the case of S. pyogenes, 
consumption of β-lactams has not resulted in the appearance 
of penicillin resistance, probably because of the absence 
of selectable variants carrying mechanisms of β-lactam 
resistance.13 In contrast, the rate of erythromycin resistance 
varies among countries, ranging from 6.9% in the USA14 
to 25.6% in Hong Kong.15 In a recent study performed in 
Eastern Europe, the rate of erythromycin resistance in S. 
pyogenes was low (,10%) in Romania and Baltic countries, 
intermediate (10%–20%) in Poland and the Czech Republic, 
and high (.25%) in Hungary and Slovakia.16 In Spain, the 
erythromycin resistance rate was 19.0% in 2006–2007.17 
In 2000, the first fluoroquinolone-resistant S. pyogenes 
isolate was reported;18 since then, reports of such isolates 
have occurred in the USA, Europe, and Japan.19–22
Haemophilus influenzae resistance to fluoroquinolones 
continues to be exceptionally rare; however, this species 
is intrinsically resistant to macrolides, which is associated 
with the presence of efflux pumps in virtually all strains.23 
Ampicillin resistance varies on a geographical and temporal 
basis, from 8.7% in South Africa to approximately 30% 
in Asia24 and the USA.25 In Europe, mean ampicillin 
resistance has been reported as 16.4%, with resistance due 
to β-lactamase production ranging from 17.6% in France 
to 0% in Germany and The Netherlands.26 With respect to 
strains showing mutations in the ftsI gene encoding PBP3 
(β-lactamase-negative ampicillin-resistant [BLNAR] strains 
and β-lactamase positive amoxicillin/clavulanate-resistant 
[BLPACR] strains), one study carried out in Europe and 
Canada in 2006–2007 showed an 11.4% prevalence of 
genotypic BLNAR.27 The country with the highest prevalence 
was Japan, with 42.9% BLNAR28 and an increase in the 
prevalence of BLPACR from 1999 to 2008.29
In vitro activity  
and pharmacokinetics/
pharmacodynamics of cefditoren
The intrinsic activity of cefditoren against S. pneumoniae 
isolates has been explored in different studies.30–41 Cefditoren 
showed high intrinsic activity against penicillin-susceptible 
strains (minimum inhibitory concentration [MIC]90 from #0.03 
to 0.06 µg/mL), with MIC90 ranging from 0.25 to 0.5 µg/mL 
against penicillin-intermediate and from 0.5 to 1 µg/mL 
against penicillin-resistant isolates. MIC values against 
penicillin-intermediate and -resistant strains were lower than 
those of amoxicillin, cefdinir, cefprozil, cefuroxime, cefixime, 
ceftibuten, cefpodoxime, erythromycin, clarithromycin, and 
azithromycin,32–41 with the MIC90 of cefditoren against peni-
cillin nonsusceptible isolates one-dilution lower than that of 
cefotaxime. In the most recently published surveillance, the 
MIC90 of cefditoren was similar to that of ceftriaxone.42
Against S. pyogenes and H. influenzae, cefditoren has 
demonstrated markedly high intrinsic activity, with an MIC90 
of #0.06 µg/mL in the studies performed.16,17,32,34,36,41,43–47 In 
the case of H. influenzae, the high intrinsic activity of cefdi-
toren was maintained against strains exhibiting ftsI mutations 
in contrast to amoxicillin/clavulanate and cefuroxime.43,45,46
Cefditoren is orally administered as cefditoren-pivoxil, 
which is further hydrolyzed during absorption and distributed 
in the blood as active cefditoren. In fasting patients, the oral 
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bioavailability of cefditoren-pivoxil is low (15%–20%), but when 
administered with high-fat meals, the mean maximum concentra-
tion (Cmax) and area under the concentration–time curve (AUC) 
values for cefditoren increase to 50% and 70%, respectively.48 In 
a Phase I study administering a single 400 mg dose of cefditoren-
pivoxil with a high-fat meal to Caucasian male subjects $18 
years of age, values of the pharmacokinetic parameters deter-
mined were: Cmax = 3.7 ± 0.7 µg/mL, time to achieve  maximum 
concentration in serum (Tmax) = 2 h, AUC0–∞ = 12.5 ± 1.6 µg × h/
mL and half-life time to achieve Cmax (Tmax) (t1/2) = 1.54 ± 0.20 
h.49 Binding to plasma proteins (primarily human serum albumin) 
averages 88% for cefditoren.48
As for all β-lactams, the pharmacokinetic/pharmacodynamic 
parameter predicting bacterial eradication and subsequent 
efficacy for cefditoren is the time (expressed as % dosing 
interval) that serum concentrations exceed the MIC of the 
infecting pathogen (% t . MIC). Values of 33% t . MIC 
are considered bacteriostatic endpoints50 and those of 40% 
t . MIC as predictive values for clinical cure in humans.51,52 
To investigate the pharmacodynamic coverage of cefditoren, 
a Monte Carlo simulation was performed53 using data from 
the mentioned Phase I study in ten healthy male volunteers, 
where 400 mg of cefditoren-pivoxil was administered 
orally as single dose after a high-fat meal.49 Cut-off values 
considered were 33% t . MIC and 40% t . MIC. Target 
attainments .90% were obtained for MICs of 0.5 µg/mL 
for total drug (using both cut-off values) and 0.25 µg/mL 
(33% t . MIC) and 0.12 µg/mL (40% t . MIC) for the 
free drug.53 This means that, using the strictest cut-off (40% 
t . MIC), concentrations obtained after administration of 
400 mg cefditoren-pivoxil cover isolates with MICs up to 
0.5 µg/mL (total drug) and up to 0.12 µg/mL (free drug), 
with a probability of $96%.53 Taking advantage of the fact 
that cefditoren protein-binding rates in mice and humans 
are almost identical, study of a pneumococcal sepsis mouse 
model was undertaken. Animals were infected with penicillin- 
intermediate and -resistant isolates (MICs of 1 and 2 µg/mL 
for penicillin and cefditoren, respectively) and 100% survival 
rates (vs 0% in untreated controls) were linked to cefditoren 
t . MIC ≈35% (free t . MIC ≈20%),54 values lower than 
those classically considered for therapeutic efficacy.
Clinical studies of efficacy
Pharyngotonsillitis
Several studies55–59 have been published on cefditoren 
in recent years, providing additional information to data 
obtained from clinical trials performed during the clinical 
development of cefditoren.60–62
The most recently published study, by Tsumura et al 
compared cefditoren-pivoxil for 5 days versus amoxicillin 
for 10 days in children with group A beta-hemolytic strep-
tococci acute tonsillopharyngitis in Japan.55 No difference 
in clinical efficacy was found between both arms (100% for 
cefditoren vs 97.9% for amoxicillin), with 100% bacterio-
logical efficacy in both groups.55 Changes in oral microflora 
were also assessed, showing absence of flora disturbance 
with cefditoren in contrast with amoxicillin, which produced 
a clear decrease in oral microbial flora.55
The same comparator was used in the study by Ozaki et al 
where children were randomized to receive either 3 mg/kg 
cefditoren-pivoxil three times daily (tid) for 5 days (103 
patients; mean age: 5.5 ± 2.3 years) or amoxicillin 10 mg/kg 
tid for 10 days (155 patients; mean age: 5.2 ± 2.0 years).56 The 
258 isolates recovered showed MIC90 values of 0.06 µg/mL 
for amoxicillin and #0.03 µg/mL for cefditoren.56 Eradication 
was 100% with amoxicillin and 99% with cefditoren-pivoxil, 
without differences in recurrence rates during the 4-week 
follow-up period: 9.7% in the amoxicillin arm and 7.8% in 
the cefditoren-pivoxil arm.56
In a different open prospective multicenter study by 
Sakata, cefditoren-pivoxil (3 mg/kg tid) was administered 
for 7 days to 90 enrolled children (age range: 8 months to 
12 years).57 A total of 79 patients complied with treatment 
intake and follow-up visits (at the end of therapy and 1 month 
after end of therapy) and were included in the efficacy 
analysis. Isolates of the same basal T type were found at the 
end of therapy in four patients and five patients presented with 
recurrence 1 month after the end of therapy (again with the 
same T type and pulsed field gel electrophoresis pattern).57
Kawamata et al evaluated the efficacy of cefditoren in 
an open multicenter study (147 centers) including a large 
number of children presenting with S. pyogenes laryngo-
pharyngitis (464 patients) or tonsillitis (254 patients).58 Age 
range was 9 months to 14 years (median age: 5 years) and 
mean daily doses were $9 mg/kg and ,13.5 mg/kg.58 The 
clinical response rate was 98.5% for laryngopharyngitis 
and 98.4% for tonsillitis.58 In the subset of patients in which 
bacteriological response could be assessed (205 for laryngo-
pharyngitis and 119 for tonsillitis), the S. pyogenes eradica-
tion rate was 94.6% and 92.4%, respectively.58
In two of these three studies performed in Japan,56,57 
the bacteriological recurrence rate ranged from 6.3% to 
9.7% in the treatment of S. pyogenes pharyngotonsillitis 
with β-lactams. It has been reported that clinical isolates 
from recurrent streptococcal pharyngitis show emm type-
specific features, with emm12 the most frequently detected   
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(expressing PrtF1 protein that allows higher invasive 
capability) followed by emm6 (more likely producing 
biofilm, thus allowing embedded S. pyogenes survival).59 
In the absence of specific resistance traits, localization 
of S. pyogenes in biofilms or inside tonsillar tissue can 
contribute to functional antibiotic resistance.63,64 In addi-
tion, with respect to β-lactams that can be hydrolyzed by 
β-lactamases, the presence of resident bacteria producing 
these inactivating enzymes (as with H. influenzae isolated 
from adeno-tonsil samples that also produces biofilms65) and 
the specific resistance traits in these indirect pathogens have 
also been proposed as an explanation for treatment failures66 
and recurrences.67
Cefditoren has been assessed in the treatment of pharyn-
gotonsillitis episodes in children presenting recurrent pharyn-
gotonsillitis. The study by Kikuta et al compared the efficacy 
obtained with 9 mg/kg tid cefditoren-pivoxil for 5 days 
versus 10 days in children (mean age: 6.77 ± 2.04 years) 
with a history of at least one previous episode of group A 
β-hemolytic streptococcal pharyngotonsillitis.68 A total of 77 
and 149 patients were included in the 5-day and 10-day treat-
ment arms, respectively.68 The frequency of previous episodes 
was 2.79 ± 1.35.68 Bacteriological failure was similar in the 
5-day treatment arm (9.1%) and the 10-day treatment group 
(11.4%), but significantly higher recurrences were found in 
the 5-day treatment group (9.1% vs 0.7%; P = 0.03).68 The 
interval between the preceding episode and the presently 
treated episode was lower (P = 0.018) in the treatment failure 
group (7.05 ± 7.31 months) than in the treatment success 
group (11.04 ± 14.57 months).68 No differences in clinical 
failure were found between groups: 18.2% in the 5-day group 
versus 12.1% in the 10-day group.68
Efficacy results of all these studies in children   carried out 
in Japan support efficacy data obtained during the clinical 
development of cefditoren outside Japan in the treatment of 
pharyngotonsillitis, including that from 1322 randomized 
patients $12 years of age analyzed in an efficacy pooled 
analysis.62 No significant differences were found between 
the clinical response obtained with cefditoren-pivoxil and 
penicillin V (95.3% vs 92.2% at end of treatment and 91.9% 
vs 89.4% at late follow-up), but eradication of S. pyogenes 
was higher with cefditoren-pivoxil in the two studies 
with microbiological assessment:60,61 90.4% versus 82.7% 
(P = 0.002) at the end of therapy and 84.7% versus 76.7% 
(P = 0.008) at the end of follow-up.62 Bacteriological efficacy 
was associated with higher clinical responses: 98.5%/99.0% 
at the end of treatment/follow-up for cefditoren-pivoxil 
and 99.3%/98.9% for penicillin V among patients showing 
bacterial eradication, in contrast to clinical responses 
of 51.4%/32.7% at the end of treatment/follow-up for 
cefditoren-pivoxil and 49.2%/41.5% for penicillin V in 
patients showing S. pyogenes persistence.62
Acute sinusitis
A recently published study of children in Thailand evaluated 
the efficacy of cefditoren in the treatment of bacterial 
rhinosinusitis.69 This randomized, investigator-blinded 
controlled study in children aged 1–15 years compared the 
clinical efficacy provided by cefditoren-pivoxil 4–6 mg/kg 
twice per day (bid) (maximum dose 300 mg/day) versus 
80–90 mg/kg/day amoxicillin amoxicillin/clavulanic acid 
(maximum dose 800 mg/day) administered bid for 14 days.69 
Changes in sinus symptoms were assessed daily by patients 
or parents using a quantitative symptom score. The primary 
outcome was rate of improvement 7 and 14 days after the 
initial visit and the secondary outcomes were relapse (defined 
as subjective rating of lack of improvement at day 21 or 28 in 
a patient rated as improved on day 14), recurrence (defined as 
sinus symptoms lasting for $10 days during the second month 
of follow-up in a patient rated as improved on day 28), and 
time to improvement.69 A total of 66 patients were evaluated 
in the cefditoren-pivoxil group and 72 in the   amoxicillin/
clavulanic acid.69 The median time to improvement was 
3.0 days in both groups, without differences in rates of 
improvement between groups: 78.8% for cefditoren-pivoxil 
versus 84.7% for amoxicillin/clavulanic acid. The differences 
in rates of relapse at day 28 (9.1% for cefditoren-pivoxil 
vs 11.1% for amoxicillin/clavulanic acid) and recurrence 
rates (3.0% for cefditoren-pivoxil vs 5.6% for amoxicillin/
clavulanic acid) were not statistically significant.69
Efficacy results from children obtained in this study are 
in accordance with efficacy rates obtained in adults in the 
clinical trials performed during the clinical development of 
cefditoren outside Japan.62,70 Data from the three clinical trials 
were analyzed in a pooled analysis.62 Regimens compared 
were cefditoren-pivoxil 200 mg or 400 mg bid for 10 days, 
cefuroxime-axetil 250 mg bid for 10 days, and amoxicillin/
clavulanic acid 875/125 mg bid for 10 days or 500/125 mg 
tid for 10 days. Clinical response was considered resolution 
or improvement in all pretreatment signs/symptoms with 
at least no worsening in the radiographic appearance of the 
sinus without the need for additional therapy. Patients were 
assessed pretherapy, at the end of treatment (within 48 hours 
of the last dose intake) and at the end of follow-up (7–14 days 
in one study and 34 ± 2 days after the last dose intake in the 
two remaining studies).62 A total of 1819 randomized patients 
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(mean age: 39.8 ± 14.3 years) were included: 1726 patients 
in the intention-to-treat and 1589 patients in the per-protocol 
populations.62 No differences (P . 0.001) in clinical response 
were found by comparing cefditoren-pivoxil 200 mg versus 
cefditoren-pivoxil 400 mg versus comparators both at the 
end of therapy (81.1% vs 80.2% vs 84.8%) and at the end 
of follow-up (72.1% vs 71.2% vs 77.4%).62
Acute otitis media
No trials in the treatment of acute otitis media were performed 
during the clinical development of cefditoren outside Japan. 
A limited number of clinical studies have been published in 
Japan using cefditoren for the treatment of acute otitis media in 
children.71–74 The most recently published study corresponds 
to a huge postmarketing study in pediatric patients with acute 
otitis media performed in 305 medical institutions with 2006 
patients.71 Age range was 1 month–14 years (median: 3 years) 
and up to 90% of patients presented with moderate/severe 
acute otitis media.71 The median daily dose of cefditoren was 
10.0 mg/kg and median total treatment period was 7 days. 
A total of 1958 patients were eligible as efficacy analysis 
population, with a clinical response rate of 93.5%.71 In 832 
patients, the causative organism was detected during the 
baseline microbiological examination, with 1217 isolates 
identified.71 S. pneumoniae (n = 397), H. influenzae (n = 393), 
and Moraxella catarrhalis (n = 166) together represented 
up to 78.6% of all isolates and 261 microorganisms were 
from other species.71 Among the 397 isolated S. pneumoniae 
strains, 58.9% were nonsusceptible to penicillin and among 
the 393 H. influenzae isolates, 28.0% were ampicillin nonsus-
ceptible (mainly BLNAR strains: 27.2%).71 The per-pathogen 
clinical response rate was 89.7% for S. pneumoniae, 90.3% 
for H. influenzae, 92.2% for M. catarrhalis, and 92.7% for 
other microorganisms.71 In patients infected by isolates 
with specific resistance traits, clinical and bacteriological 
responses were 88% and 85.7%, respectively, for penicillin-
intermediate pneumococci; 90.1% and 77.5%, respectively, 
for penicillin-resistant pneumococci; and 92.5% and 81.8%, 
respectively, for BLNAR H. influenzae.71
Lower respiratory tract infections
No further clinical studies have been published with cefdi-
toren in the treatment of lower respiratory tract infections 
apart from those performed during the clinical development 
of cefditoren (four studies in community-acquired pneu-
monia [CAP] and three studies in acute exacerbations of 
chronic bronchitis [AECB]). Data from these clinical trials 
were pooled and analyzed by comparing cefditoren with 
comparators (amoxicillin/clavulanic acid, cefuroxime-axetil, 
cefpodoxime, and clarithromycin) in a previous publication.75 
The per-pathogen bacteriological response was determined 
by pooling data from CAP and AECB studies. Response was 
defined as eradication or presumed eradication (absence of 
sputum for culture in a patient with clinical response).75 A total 
of 406 S. pneumoniae isolates (56 of them nonsusceptible to 
oral penicillin) were recovered prior to treatment initiation, 
with similar bacteriological response rates for cefditoren and 
comparators (88.5% for cefditoren-pivoxil 200 mg, 92.0% 
for cefditoren-pivoxil 400 mg, and 89.9% for comparators).75 
Of the 56 penicillin nonsusceptible (MIC $ 0.12 µg/mL) 
S. pneumoniae isolates recovered, all those isolated from 
patients in the cefditoren-pivoxil 400 mg group (n = 20), 
16/19 (84.2%) in the cefditoren-pivoxil 200 mg group, and 
16/17 (94.1%) in the comparators group were eradicated or 
presumed eradicated.75 Up to 29 of the 56 nonsusceptible 
isolates were penicillin resistant (MIC $ 2 µg/mL), 18 in the 
cefditoren-pivoxil arm and eleven in the comparators group. 
Eradication or presumed eradication rates among patients 
with penicillin-resistant initial isolates were 94.4% (17/18) for 
cefditoren (pooled 200 mg and 400 mg) and 90.9% (10/11) for 
comparators.75 H. influenzae was isolated in baseline cultures 
of 595 patients: 224 patients in the cefditoren-pivoxil 200 mg 
arm, 175 in the cefditoren-pivoxil 400 mg arm, and 196 in 
the group of pooled comparators.75 Bacteriological response 
rates were similar in all groups: 86.6% for cefditoren-pivoxil 
200 mg versus 85.7% for cefditoren-pivoxil 400 mg versus 
82.7% for comparators.75
For the clinical response analysis, data from AECB and 
CAP studies were analyzed separately. Pooled analyses 
included 1379 patients with CAP and 1560 patients with 
AECB as the overall efficacy populations.75 Similar clinical 
response rates were obtained for cefditoren-pivoxil 200 mg 
(91.8%), cefditoren-pivoxil 400 mg (89.2%), and compara-
tors (91.5%) at the end of therapy and at the end of follow-up 
(87.8% vs.85.9% vs. 90.4%, respectively) in CAP stud-
ies.75 Similar response rates were found in AECB studies: 
cefditoren-pivoxil 200 mg (85.8%) versus cefditoren-pivoxil 
400 mg (91.3%) versus comparators (87.1%) at the end of 
therapy and 81.3% versus 81.2% versus 83.3%, respectively, 
at the end of follow-up.75 However, slightly higher efficacy 
was obtained with 400 mg cefditoren-pivoxil (vs 200 mg) by 
the end of therapy (91.3% vs 85.8%, P = 0.014).75
Safety and tolerability issues
Safety data from 13 clinical trials carried out in adults during 
the clinical development of cefditoren outside Japan for the 
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treatment of community-acquired respiratory infections were 
analyzed in a pooled analysis and showed that the adverse 
event profiles of cefditoren-pivoxil and comparators are 
similar.76 For both groups, diarrhea was the most frequent 
adverse event (9.9% for cefditoren vs 6.9% for comparators) 
followed by vaginosis among female populations (3.9% vs 
4.6%), nausea (3.5% vs 3.6%), abdominal pain (1.8% vs 
1.1%), and dyspepsia (1.1% vs 0.9%).76
New data from recently published studies update the 
information mainly with data from children in Japan. In a 
postmarketing surveillance evaluating safety in 2006 children 
with acute otitis media treated with cefditoren-pivoxil (median 
daily dose: 10.0 mg/kg with a median total treatment period of 
7 days), the incidence of adverse reactions was 1.79%, without 
unexpected or serious adverse drug reactions reported.71 The 
most frequent adverse drug reaction was diarrhea (1.30%) that 
resolved or subsided during cefditoren-pivoxil treatment or 
after discontinuation or completion of therapy in all cases.71 
Data from the clinical studies carried out with cefditoren in the 
treatment of pharyngotonsillitis from 2007 to 2010 in Japan 
showed that the percentage of adverse events was very low 
and diarrhea was the most frequent event.56–58 In the largest 
study (734 children), the incidence of adverse reactions was 
1.50% (eleven events in eleven patients), with three events of 
diarrhea and three of hematuria in urinalysis without clinical 
symptoms.58 In a study carried out in children in Thailand 
comparing cefditoren-pivoxil (66 patients) with amoxicillin/
clavulanic acid (72 patients) for 10 days in the treatment of 
acute bacterial rhinosinusitis, the most frequent adverse event 
was diarrhea, with significant (P = 0.02) differences in the 
percentages found for both compounds (4.5% with cefditoren-
pivoxil vs 18.1% for amoxicillin/clavulanic acid).69
Patients ingesting pivalic acid containing prodrugs may 
develop hypocarnitinemia.77 However, it has been reported 
that net carnitine losses after cefditoren-pivoxil administra-
tion are ,10% of body stores, thus it is not likely to result 
in adverse effects.78 Carnitine metabolism was studied in 16 
pediatric patients under treatment with cefditoren-pivoxil, 
with increased carnitine excretion and a decrease in free 
carnitine in serum that disappeared when dosing was termi-
nated without carnitine-related side effects.79 Nevertheless, 
two reports on clinical manifestations of hypocarnitinemia 
after cefditoren-pivoxil administration can be found in the 
literature: one reporting a carnitine-associated encephal-
opathy within hours of cefditoren-pivoxil administration 
for infection control after hysterectomy in a 47-years old 
woman80 and the other in an 18-month child after 6 months 
of treatment for untreatable acute otitis media.81
Optimizing cefditoren use
The most prevalent respiratory infections in the community 
are pharyngotonsillitis, otitis media, sinusitis, AECB, and 
CAP, with S. pyogenes the most prevalent bacterial isolate 
from pharyngotonsillitis and S. pneumoniae and H. influenzae 
the most prevalent from the latter four infections. New 
antibiotics aiming to treat community respiratory infections 
should address the current issue of these bacterial species’ 
resistance to common antibiotics.
As previously described, the main resistance issues in 
terms of H. influenzae is their resistance to macrolides in 
virtually all strains due to efflux pumps23 and the increasing 
prevalence of BLNAR and BLPACR phenotypes in certain 
geographical areas.27–29 These phenotypes/genotypes 
should be considered resistant to oral β-lactams such as 
amoxicillin, amoxicillin/clavulanic acid, cefaclor, and 
cefuroxime.82 Nontypable H. influenzae is one of the most 
common bacterial causes of AECB.83 It has been postulated 
that, with eradication, fewer viable pathogens remain in 
the bronchial tissue after antimicrobial treatment, requiring 
a longer period for the bacterial population to increase 
sufficiently to induce a new exacerbation,84 although the 
acquisition of new strains has also been associated with an 
increased risk of new exacerbations.85 Cefditoren may play 
an important therapeutic role in areas with significant rates of 
BLNAR/BLPACR phenotypes in the treatment of infections 
potentially caused by H. influenzae such as AECB.
During its clinical development, clinical trials of cefdi-
toren in the treatment of lower respiratory tract infections 
showed its capability for eradication or presumed eradica-
tion of S. pneumoniae, including penicillin-intermediate 
and -resistant strains.75 Introduction of conjugate vaccines has 
produced a shift in serotype distribution (with their associated 
nonsusceptibility). There has been a decrease in PCV7 sero-
types (associated with a decrease in penicillin/erythromycin 
nonsusceptibility), with an increase in non-PCV7 serotypes 
(some of them, as serotype 19A, non susceptible to penicillin). 
Although cefditoren exhibited an intrinsic activity higher than 
that of other β-lactams against these serotypes,86 there are no 
clinical studies showing the specific activity of cefditoren or 
other compounds against these emerging serotypes.
In addition, it has been pointed out that cefditoren may 
be the logical option for sequential therapy after intravenous 
treatment with cefotaxime or ceftriaxone for S. pneumoniae 
CAP.87 This is based on cefditoren’s spectrum and intrinsic 
in vitro activity, which is similar to that of intravenous 
third-generation cephalosporins (cefotaxime or ceftriaxone), 
together with its pharmacodynamic adequacy.87
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Macrolide resistance is the main resistance issue in 
S. pyogenes, but strains are uniformly susceptible to all 
β-lactams. However, clinical failures of penicillin/amoxicillin 
treatment derived from indirect protection of S. pyogenes by 
β-lactamases produced by M. catarrhalis or H. influenzae 
have been reported.88 Indirect protection of S. pyogenes 
could also affect amoxicillin/clavulanic acid efficacy when 
BLPACR strains are present, as has occurred in vitro.66 
Oral β-lactams resistant to β-lactamases such as cefditoren 
could offer advantages by countering indirect pathogenicity, 
although clinical effects of indirect pathogenicity have been 
criticized by some authors.89,90
Conclusion
Cefditoren is a third-generation cephalosporin active against 
the principal community-acquired respiratory tract pathogens 
(including resistance phenotypes) that has demonstrated effi-
cacy and safety in comparative clinical trials in adults with 
AECB, CAP, sinusitis, or pharyngotonsillitis.
The results of new clinical studies of cefditoren in the 
treatment of pharyngotonsillitis, sinusitis, and otitis media 
in children, mainly in Japan, support the adequacy of 
cefditoren for the treatment of these community-acquired 
respiratory tract infections and demonstrate that cefdi-
toren has a safety profile similar to that of previous oral 
β-lactams. Cefditoren may be an interesting option in the 
pediatric field where fluoroquinolones are not indicated. 
Nevertheless, additional clinical trials in pediatric otitis 
media are needed, since penetration to middle-ear fluid 
is unknown.
Cefditoren is thus indicated for the treatment of 
mild-to-moderate community-acquired respiratory tract infec-
tions (when it is feasible for medication to be taken with meals) 
particularly in geographical areas with a reported prevalence 
of phenotypes exhibiting nonsusceptibility to common oral 
antibiotics among community respiratory pathogens.
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